Pharmacodynamics of Ceftiofur Selected by Genomic and Proteomic Approaches of Isolated from the Flounder, .

We employed an integrative strategy to present subtractive and comparative metabolic and genomic-based findings of therapeutic targets against . For the first time, we not only identified potential targets based on genomic and proteomic database analyses but also recommend a new antimicrobial drug for the treatment of olive flounder () infected with . To do that, 102 total annotated metabolic pathways of this bacterial strain were extracted from computational comparative metabolic and genomic databases. Six druggable proteins were identified from these metabolic pathways from the DrugBank database with their respective genes as mtnN, penA, pbp2, , A, coaA, and fni out of 112 essential nonhomologous proteins. Among these hits, 26 transmembrane proteins and 77 cytoplasmic proteins were extracted as potential vaccines and drug targets, respectively. From the FDA DrugBank, ceftiofur was selected to prevent antibiotic resistance as it inhibited our selected identified target. Florfenicol is used for treatment of infection in flounder and was chosen as a comparator drug. All tested strains of fish isolates with were susceptible to ceftiofur and florfenicol with minimum inhibitory concentrations (MIC) of 0.0039-1 g/mL and 0.5-8 g/mL, IC of 0.001-0.5 g/mL and 0.7-2.7 g/mL, and minimum biofilm eradication concentrations (MBEC) of 2-256 g/mL and 4-64 g/mL, respectively. Similar susceptibility profiles for ceftiofur and florfenicol were found, with ceftiofur observed as an effective and potent antimicrobial drug against both planktonic and biofilm-forming strains of the fish pathogen , and it can be applied in the aquaculture industry. Thus, our predictive approach not only showed novel therapeutic agents but also indicated that marketed drugs should also be tested for efficacy against newly identified targets of this important fish pathogen.